Rosa Bonavia

Statistics

Publications

Citations

268

H-Index

Active since

2013

Affiliations

Institut d'Investigació Biomédica de Bellvitge(Current)

Institut Català d'Oncologia

Institut d'Investigació Biomèdica de Girona

Catalan Institute for Water Research

Universitat Rovira i Virgili

Rosa Bonavia is an author at Institut d'Investigació Biomédica de Bellvitge specializing in oncogenic signaling pathways, oncology, and molecular oncology.

Publications per year

2013–2013

Publications

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

Alejandro Vázquez‐Martín, Sílvia Cufí, Cristina Oliveras‐Ferraros et al. · Scientific Reports · 2013 · 95 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

Sílvia Cufí, Rosa Bonavia, Alejandro Vázquez‐Martín et al. · Scientific Reports · 2013 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

Sílvia Cufí, Rosa Bonavia, Alejandro Vázquez‐Martín et al. · Food and Chemical Toxicology · 2013 · 64 citations

Medicine, Oncology, Pharmacology +15

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

Sílvia Cufí, Bruna Corominas-Faja, Eugeni López‐Bonet et al. · Oncotarget · 2013 · 32 citations · Full text

Medicine, Oncology, Pathology +14

1–4 of 4